Paxman publ : publishes newsletter on NCCN’s inclusion of scalp cooling in its guidelines for ovarian cancer and updates on pre-emptive coronavirus measures

Today, PAXMAN publishes a special issue of its newsletter aimed at shareholders, investors and other interested parties.

This issue focuses on the decision by the National Comprehensive Cancer Network® (NCCN®) to include scalp cooling as a recommended category 2A treatment to prevent alopecia for ovarian cancer patients. Since the NCCN included a corresponding recommendation for breast cancer patients in 2019, PAXMAN has seen an increasing patient enrolment in the US, and the company now expects a similar, albeit less substantial, positive effect.

In this issue, PAXMAN also outlines the company’s forceful, temporary program to reduce its operational costs as a pre-emptive measure due to lower demand for Q2 2020 caused by the coronavirus situation. However, the company has seen strong sales throughout Q1 2020, and has not seen any drop in patient enrolments in the US so far.

To read the newsletter, and subscribe to receive upcoming issues, follow this link:

https://bit.ly/paxapr20xen

PAXMAN’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on PAXMANs website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

For more information, please contact:

Richard Paxman, CEO
Tel: [phone]
Email: [e-mail]
www.paxman.se

About PAXMAN
The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,000 systems delivered to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via [e-mail] and [phone].

Contacts

---

Richard Paxman, CEO
Tel: [phone]
Email: [e-mail]
www.paxman.se

About Us

---

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company’s Certified Adviser and can be contacted via [e-mail] and [phone].

Attachments

---

PAXMAN publishes newsletter on NCCN’s inclusion of scalp cooling in its guidelines for ovarian cancer and updates on pre-emptive coronavirus measures

© Modular Finance, source Nordic Press Releases